Project Details
Description
A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma
| Status | Finished |
|---|---|
| Effective start/end date | 8/14/19 → 8/30/24 |
Funding
- TAKEDA CAMBRIDGE LTD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.